ID   MVX-1
AC   CVCL_C3M8
SY   MaxiVaX-1
DR   Wikidata; Q116049837
RX   DOI=10.1093/annonc/mdw378.12;
RX   Patent=US11013790;
CC   Group: Patented cell line.
CC   Population: Caucasian.
CC   Biotechnology: Used in clinical trial of MVX-ONCO-1 a cancer immunotherapy method using cell encapsulation technology that contains dead tumor cells from the patient itself and MVX-1 cells that produce CSF2.
CC   Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL; Note=BCR exon 14 fused to ABL1 exon 2 (b3a2 transcript) (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln136fs*13 (c.406_407insC); Zygosity=Homozygous (from parent cell line).
CC   Transfected with: HGNC; 2434; CSF2.
CC   Derived from site: In situ; Pleural effusion; UBERON=UBERON_0000175.
DI   NCIt; C9110; Blast phase chronic myelogenous leukemia, BCR-ABL1 positive
DI   ORDO; Orphanet_521; Chronic myeloid leukemia
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0004 ! K-562
SX   Female
AG   53Y
CA   Cancer cell line
DT   Created: 15-12-22; Last updated: 02-05-24; Version: 4
//
RX   DOI=10.1093/annonc/mdw378.12;
RA   Mach N., Vernet R., Belkouch M.-C., Luy P., Ancrenaz V., Teta P.,
RA   Blazek N., Grandjean N., Wasem J., Grogg J., Perez T., Migliorini D.;
RT   "MVX-ONCO-1 phase 1 final results of the first personalized cell-based
RT   immunotherapy using cell encapsulation technology.";
RL   Ann. Oncol. 27 Suppl. 6:vi359-vi378(2016).
//
RX   Patent=US11013790;
RA   Mach N.;
RT   "Vaccination with immuno-isolated cells producing an immunomodulator.";
RL   Patent number US11013790, 25-May-2021.
//